UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different

Trends in immunology, 2018-07, Vol.39 (7), p.536-548

2018

Volltextzugriff (PDF)

Multiple imputation confidence intervals for the mean of the discrete distributions for incomplete data

Statistics in medicine, 2022-03, Vol.41 (7), p.1172-1190

2022

Volltextzugriff (PDF)

An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma

Cancer cell, 2016-01, Vol.29 (1), p.104-116

2016

Volltextzugriff (PDF)

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial

The lancet oncology, 2023-08, Vol.24 (8), p.881-891

2023

Volltextzugriff (PDF)

New approaches to first-line treatment of advanced renal cell carcinoma

Therapeutic Advances in Medical Oncology, 2021, Vol.13, p.17588359211034708-17588359211034708

2021

Volltextzugriff (PDF)

Mitochondrial Dysfunction in Down Syndrome: From Pathology to Therapy

Neuroscience, 2023-02, Vol.511, p.1-12

2023

Volltextzugriff (PDF)

Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial

Cancer, 2020-12, Vol.126 (24), p.5247-5255

2020

Volltextzugriff (PDF)

Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma

British journal of cancer, 2018-10, Vol.119 (8), p.911-912

2018

Volltextzugriff (PDF)

Immunometabolic coevolution defines unique microenvironmental niches in ccRCC

Cell metabolism, 2023-08, Vol.35 (8), p.1424-1440.e5

2023

Volltextzugriff (PDF)

Genomic ancestry in kidney cancer: Correlations with clinical and molecular features

Cancer, 2024-03, Vol.130 (5), p.692-701

2024

Volltextzugriff (PDF)

A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma

Cancer treatment reviews, 2014-05, Vol.40 (4), p.533-547

2014

Volltextzugriff (PDF)

Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations

European urology, 2023-03, Vol.83 (3), p.195-199

2023

Volltextzugriff (PDF)

Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin

The Journal of clinical investigation, 2016-09, Vol.126 (9), p.3526-3540

2016

Volltextzugriff (PDF)

Confidence intervals for the proportion of conformance

Journal of statistical computation and simulation, 2021-05, Vol.91 (8), p.1564-1579

2021

Volltextzugriff (PDF)

Water-Extracted Ganoderma lucidum Induces Apoptosis and S-Phase Arrest via Cyclin-CDK2 Pathway in Glioblastoma Cells

Molecules (Basel, Switzerland), 2020-08, Vol.25 (16), p.3585

2020

Volltextzugriff (PDF)

Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma

British journal of cancer, 2021-01, Vol.124 (1), p.237-246

2021

Volltextzugriff (PDF)

Trace gas oxidation sustains energy needs of a thermophilic archaeon at suboptimal temperatures

Nature communications, 2024-04, Vol.15 (1), p.3219-3219, Article 3219

2024

Volltextzugriff (PDF)

Phenotype microarrays reveal metabolic dysregulations of neurospheres derived from embryonic Ts1Cje mouse model of Down syndrome

PloS one, 2020-07, Vol.15 (7), p.e0236826-e0236826

2020

Volltextzugriff (PDF)

Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53

The EMBO journal, 2007-11, Vol.26 (23), p.4812-4823

2007

Volltextzugriff (PDF)

Combination therapy for advanced and metastatic kidney cancer

Nature reviews. Urology, 2019-02, Vol.16 (2), p.77-78

2019

Volltextzugriff (PDF)

mTOR pathway as a target in tissue hypertrophy

Annual review of pharmacology and toxicology, 2007-01, Vol.47 (1), p.443-467

2007

Volltextzugriff (PDF)

DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy

Journal for immunotherapy of cancer, 2020-06, Vol.8 (1), p.e000230

2020

Volltextzugriff (PDF)

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy

Journal for immunotherapy of cancer, 2022-11, Vol.10 (11), p.e005780

2022

Volltextzugriff (PDF)

Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Scientific reports, 2021-02, Vol.11 (1), p.3847-15, Article 3847

2021

Volltextzugriff (PDF)

1 – 25 von 1.013

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(833)
Mit Volltextzugriff
(764)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(604)
Life Sciences & Biomedicine
(436)
Humans
(269)
Male
(171)
Female
(151)
Middle Aged
(130)
Technology
(123)
Adult
(118)
Physical Sciences
(105)
Aged
(102)
Biological And Medical Sciences
(92)
Engineering
(78)
Oncology
(71)
Chemistry
(70)
Medical Sciences
(70)
Animals
(62)
Materials Science
(51)
Retrospective Studies
(48)
Radiology, Nuclear Medicine & Medical Imaging
(45)
Treatment Outcome
(43)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different

Multiple imputation confidence intervals for the mean of the discrete distributions for incomplete data

An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

New approaches to first-line treatment of advanced renal cell carcinoma

Mitochondrial Dysfunction in Down Syndrome: From Pathology to Therapy

Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial

Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma

Immunometabolic coevolution defines unique microenvironmental niches in ccRCC

Genomic ancestry in kidney cancer: Correlations with clinical and molecular features

A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma

Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations

Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin

Confidence intervals for the proportion of conformance

Water-Extracted Ganoderma lucidum Induces Apoptosis and S-Phase Arrest via Cyclin-CDK2 Pathway in Glioblastoma Cells

Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma

Trace gas oxidation sustains energy needs of a thermophilic archaeon at suboptimal temperatures

Phenotype microarrays reveal metabolic dysregulations of neurospheres derived from embryonic Ts1Cje mouse model of Down syndrome

Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53

Combination therapy for advanced and metastatic kidney cancer

mTOR pathway as a target in tissue hypertrophy

DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy

Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice

Suchergebnisse filtern